Importantly, a small-molecule ALKBH5 inhibitor enhanced the efficacy of cancer immunotherapy in melanoma (82), suggesting that the combination of FTO/ALKBH5 inhibition with anti-PD-1 blockade may reduce the resistance to immunotherapy in melanoma. The gene discussed is FTO; the disease is melanoma.